SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Adobe, Inc. is a global technology company, which engages in the provision of digital marketing and media solutions. It operates through the following segments: Digital Media, Digital Experience, and Publishing and Advertising. The Digital Media segment offers products and services that enable individuals, teams, businesses, and enterprises to create, publish, and promote content anywhere and accelerate productivity by transforming view, share, engage with and collaborate on documents and creative content. The Digital Experience segment focuses on integrated platform and set of products, services, and solutions that enable businesses to create, manage, execute, measure, monetize, and optimize customer experiences that span from analytics to commerce. The Publishing and Advertising segment includes legacy products and services that address diverse market opportunities, including eLearning solutions, technical document publishing, web conferencing, document and forms platform, web app development, high-end printing, and Adobe Advertising offerings. The company was founded by Charles M. Geschke and John E. Warnock in December 1982 and is headquartered in San Jose, CA.

Adobe Inc

Adobe is trending following a significant leadership transition announcement, with CEO Shantanu Narayen set to step down while the company maintains strong earnings beats and reaffirmed guidance. The community remains deeply divided, with some investors viewing the price drop as a prime buying opportunity for a financially healthy company, while others express concerns that artificial intelligence is structurally eroding its competitive moat.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is experiencing a surge in social media attention as its community rallies behind a 'culture-first' narrative ahead of April 20, drawing comparisons to Bitcoin's trajectory. Supporters are actively engaging in educational discussions around cannabis-related scientific research and policy trends while leveraging the Solana ecosystem to promote the token's growth.

Lightwave Logic, Inc. is a development stage company which engages in the commercialization of electro-optic photonic devices. The firm offers the P2ICTM technology platform which uses in-house proprietary organic polymers. Its products include electro-optical modulation devices and proprietary polymer photonic integrated circuits. The company was founded on June 24, 1997 and is headquartered in Englewood, CO.

Lightwave Logic Inc

Lightwave Logic is seeing significant market activity and community interest following a development agreement with Tower Semiconductor to integrate its electro-optic polymer modulators into the PH18 silicon photonics platform. Traders are actively debating the stock's potential for AI infrastructure integration versus concerns over its pre-revenue status and dilution risks, while many are focused on upcoming industry conferences as potential catalysts for further momentum.

BRC Group Holdings, Inc. engages in the provision of financial services and solutions to the capital raising and financial advisory needs of public and private firms. It operates through the following segments: Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications, and Consumer. The Capital Markets segment provides investment banking, corporate finance, research, wealth management, and sales and trading services to corporate, institutional, and high net worth clients. The Wealth Management segment offers retail brokerage, investment management, and insurance, and tax preparation services. The Financial Consulting segment focuses on a variety of specialized advisory services spanning bankruptcy, restructuring, turnaround management, forensic accounting, crisis and litigation support, appraisal and valuation, real estate, and operations management. The Auction and Liquidation segment deals with retail liquidation services. The Communications segment is composed of a portfolio of companies acquired for attractive risk-adjusted investment return characteristics. The Consumer segment includes Targus and the Brands investment portfolio. The company was founded in 1973 and is headquartered in Los Angeles, CA.

BRC Group Holdings Inc.

B. Riley Financial Inc

B. Riley Financial is trending as investors debate the binary outcome of recent short-seller allegations, with the community closely tracking the company's aggressive debt reduction efforts and potential short squeeze dynamics. Bullish participants are pointing to the firm's significant holdings in companies like $BW and $APLD as undervalued assets, while some remain cautious due to ongoing filing delays and high volatility.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is seeing a surge in investor attention and volume as the community anticipates major product demonstrations at the upcoming OFC Conference. The conversation is heavily focused on the company's potential for scaling production of its optical engines to address AI data center bottlenecks, with many investors actively tracking partnerships and speculating on looming commercial announcements.

Nasdaq, Inc. is a holding company, which engages in trading, clearing, exchange technology, regulatory, securities listing, information, and public and private company services. It operates through the following segments: Capital Access Platforms, Financial Technology, and Market Services. The Capital Access Platforms segment delivers liquidity, transparency, and integrity to the corporate issuer and investment community by empowering clients to effectively navigate the capital markets, achieve their sustainability goals, and drive governance excellence. The Financial Technology segment offers platforms that improve the liquidity, transparency, and integrity of the global economy by architecting and operating the markets. The Market Services segment includes equity derivative trading and clearing, cash equity trading, fixed income, currency, and commodities trading. The company was founded by Gordon S. Macklin in 1971 and is headquartered in New York, NY.

Nasdaq Inc - Ordinary Shares - 144A

Nasdaq Inc

Nasdaq Inc. is trending as investors monitor its upcoming quarterly earnings report and strategic AI-powered enhancements to its market surveillance platform. The broader community remains focused on how the exchange's diversification into digital assets and technology infrastructure positions it against shifting macroeconomic conditions and potential market volatility.

ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I allergic reactions including anaphylaxis. Its product includes Epinephrine Nasal Spray. The company was founded by Richard Lowenthal, Robert Bell, and Sarina Tanimoto on August 5, 2015 and is headquartered in San Diego, CA.

ARS Pharmaceuticals Inc

SPRY is currently experiencing heightened community interest driven by its position as the first-to-market needle-free epinephrine treatment, with investors closely monitoring its global expansion efforts and potential short squeeze dynamics. While some market participants debate the long-term competition from pending alternative treatments, others are focused on the stock's constrained float and fundamental progress in scaling adoption for anaphylaxis and urticaria.

|The Artificial Superintelligence (ASI) Alliance is the world’s largest open-source initiative dedicated to decentralized Artificial General Intelligence (AGI). Formed in April 2024, the ASI Alliance unites SingularityNET, Fetch.ai, and Ocean Protocol, with CUDOS joining as a network member shortly after. The ASI Alliance was established through a community-approved tokenomic merger—combining $AGIX, $FET, and $OCEAN into a single token: $FET. This unified token underpins a collaborative framework designed to scale open-source AI and stand as the largest open-sourced, independent entity in AI research and development. The Alliance is committed to accelerating the advancement of decentralized Artificial General Intelligence (AGI) and, ultimately, Artificial Superintelligence (ASI). It provides a robust, open-source innovation stack, empowering developers, enterprises, and researchers globally to build ethical, scalable, and groundbreaking AI solutions. This ensures that advanced intelligence remains a shared, accessible resource, fostering innovation beyond centralized systems and promoting a future where AI benefits all.

Fetch.ai

Fetch.ai is trending as investors actively debate its long-term potential amid significant price volatility and ongoing community discussions regarding the impact of the ASI alliance and strategic partnerships. The community remains polarized, with many buyers viewing current price levels as a deep-discount accumulation opportunity, while others express frustration over recent performance and skepticism regarding broader market conditions.

Taiwan Semiconductor Manufacturing Co., Ltd. engages in the manufacture and sale of integrated circuits and wafer semiconductor devices. Its chips are used in personal computers and peripheral products, information applications, wired and wireless communications systems products, and automotive and industrial equipment including consumer electronics such as digital video compact disc player, digital television, game consoles, and digital cameras. The company was founded by Chung Mou Chang on February 21, 1987 and is headquartered in Hsinchu, Taiwan.

Taiwan Semiconductor Manufacturing - ADR

TSM is trending as investors weigh strong AI-driven demand and record revenue growth against heightened geopolitical risks regarding the Taiwan Strait and potential shifts in global supply chain dependency. Community discussions are actively split between those viewing the stock as a mandatory long-term AI cornerstone and traders utilizing options to hedge against volatility from regional tensions and capacity-related news.

CF Industries Holdings, Inc. engages in the manufacture and distribution of nitrogen fertilizer. The firm owns and operates nitrogen plants and serves agricultural and industrial customers through its distribution system. It operates through the following segments: Ammonia, Granular Urea, UAN, AN, and Other. The Ammonia segment produces anhydrous ammonia. The Granular Urea segment offers granular urea. The UAN segment focuses on urea ammonium nitrate solution. The AN segment refers to the production of ammonium nitrate. The Other segment includes diesel exhaust fluid, nitric acid, urea liquor, and aqua ammonia. The company was founded in 1946 and is headquartered in Northbrook, IL.

CF Industries Holdings Inc

CF Industries is trending as investors weigh strong operational results against concerns over nitrogen price volatility and global demand shifts. Community discussions are heavily focused on the company's valuation, its strategic pivot toward low-carbon ammonia, and how the ongoing energy cost landscape impacts future growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Alvotech (NASDAQ:ALVO) Hits New 52-Week Low - Time to Sell?

Alvotech (NASDAQ:ALVO) Hits New 1-Year Low - Should You Sell...

Alvotech (ALVO) Projected to Post Earnings on Wednesday

Alvotech (NASDAQ:ALVO) will be releasing its Q4 2025 earnings after the market closes on Wednesday, March 18. (View Earnings Report at...

Alvotech (NASDAQ:ALVO) Sets New 12-Month Low - Should You Sell?

Alvotech (NASDAQ:ALVO) Sets New 1-Year Low - Should You Sell...

Alvotech (NASDAQ:ALVO) Given Average Recommendation of "Reduce" by Analysts

Alvotech (NASDAQ:ALVO - Get Free Report) has been given an average rating of "Reduce" by the six ratings firms that are covering the stock, MarketBeat.com reports. Three research analysts have rated...

Alvotech (NASDAQ:ALVO) Reaches New 1-Year Low - Here's Why

Alvotech (NASDAQ:ALVO) Hits New 12-Month Low - Time to Sell...

Alvotech (NASDAQ:ALVO) Trading Down 5.7% - Here's Why

Alvotech (NASDAQ:ALVO) Shares Down 5.7% - Here's Why...

Rosen Law Firm Encourages Alvotech Investors to Inquire About Securities Class Action Investigation - ALVO

Rosen Law Firm Encourages Alvotech Investors to Inquire About Securities Class Action Investigation - ALVO Rosen Law Firm Encourages Alvotech Investors to Inquire About Securities Class Action...

<ul class="summary-bullets"><li>Alvotech stated that it designed the study to evaluate the safety, tolerability, and immunogenicity profiles of AVT80 and Entyvio in healthy adult participants following subcutaneous administration.</li><li>Entyvio is indicated for the treatment of moderate to severe Ulcerative Colitis and moderate to severely active Crohn’s disease in adult patients.</li><li>The biologic medication’s cumulative worldwide net revenue in 2025 was about $6.4 billion, the company said.</li></ul>Alvotech (ALVO) shares were up nearly 10% in Thursday’s pre-market trade after the company announced positive top-line results from its pharmacokinetic study.The company stated that the study showed that AVT80, its biosimilar candidate to Entyvio, met all its primary endpoints.“We are very pleased with this result, which is an important milestone in the development of our proposed biosimilar to Entyvio, allowing us to proceed towards regulatory submissions,” said Alvotech COO Joseph McClellan.<h2 class="st-heading-2">Details Of The Pharmacokinetics Study</h2>Alvotech stated that it designed the study to evaluate the safety, tolerability, and immunogenicity profiles of AVT80 and Entyvio in healthy adult participants following a single 108 mg/0.68 mL subcutaneous (SC) injection.Entyvio is indicated for the treatment of moderate to severe Ulcerative Colitis and moderate to severely active Crohn’s disease in adult patients. The biologic medication’s cumulative worldwide net revenue in 2025 was about $6.4 billion, the company said.Alvotech also stated that it is currently developing AVT16, a proposed biosimilar to Entyvio for intravenous administration, while AVT80 is designed for subcutaneous administration.The Pharmacokinetic study for AVT80 is crucial to demonstrating clinical similarity between AVT16 and AVT80, the company added.<h2 class="st-heading-2">What Does Alvotech Do?</h2>Alvotech is a Reykjavik, Iceland-based biotechnology company that is focused exclusively on developing biosimilar medicines.The company has two biosimilars, Humira and Stelara, already approved and marketed in multiple markets around the world. Alvotech has partnered with multiple companies globally, including Teva Pharmaceuticals, Cipla, Dr. Reddy’s, and Lotus Pharmaceuticals, among others.&nbsp;<h2 class="st-heading-2">How Stocktwits Users Reacted</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/ALVO">Alvotech</a> was in the ‘bullish’ territory, with message volumes at ‘extremely high’ levels. The ALVO ticker was the fourth most trending ticker on the platform at the time of writing.One bullish user called the top-line results “huge news” for Alvotech.<stembedurl>https://stocktwits.com/NewsTrader_perform4nce/message/644068023</stembedurl><a href="https://stocktwits.com/symbol/ALVO">ALVO stock</a> is down 1% year-to-date and 59% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-excellent-call-with-china-xi-jinping-trip-in-april/cZbj5hCR4Z6">Trump Announces He Had An ‘Excellent’ Call With Chinese President Xi Jinping, Says He Will Travel In April To China</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Alvotech logo is seen displayed on a smartphone screen

Why Is ALVO Stock Rising Pre-Market Today?

The company reported that the study showed AVT80, its biosimilar candidate to Entyvio, met all primary endpoints.

Equity

Alvotech (NASDAQ:ALVO) Given Consensus Recommendation of "Hold" by Brokerages

Shares of Alvotech (NASDAQ:ALVO - Get Free Report) have earned an average recommendation of "Hold" from the six research firms that are covering the company, MarketBeat.com reports. Two analysts have...

Dr. Reddy's Q3 Earnings Match Estimates, Revenues Rise Y/Y

RDY posts flat Q3 earnings, while revenues miss estimates as global generics growth lagged, pressured by weaker North America sales.

Alvotech is a biotechnology company, which engages in the development and manufacture of biosimilar medicines. The firm is focusing on the development of its product candidates. It operates through the following geographical segments: Europe, North America, Asia, and Other. The company was founded by Róbert Vilhelm Wessman in 2013 and is headquartered in Luxembourg.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.01	--	--	N/A
Q3 '25	-$0.03	-$0.10	-275.56%	MISSED
Q2 '25	-$0.05	$0.03	165.54%	BEAT
Q1 '25	-$0.11	$0.35	408.96%	BEAT
Q4 '24	-$0.03	--	--	N/A

ALVO
Alvotech

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest ALVO News

ALVOAlvotech